The GIT1 (G protein-coupled receptor kinase-interacting protein 1) antibody is a tool used to detect GIT1. a multidomain protein involved in diverse cellular processes. GIT1 belongs to the GIT protein family and acts as a scaffold/adaptor protein, interacting with signaling molecules like G protein-coupled receptors (GPCRs), kinases (e.g., PAK, MEK), and cytoskeletal regulators (e.g., βPIX, paxillin). It contains an ARF-GAP domain, which regulates ARF GTPases, and plays roles in cell adhesion, migration, vesicular trafficking, and synaptic plasticity.
GIT1 is highly expressed in the brain, where it modulates neurotransmitter receptor trafficking and dendritic spine formation, linking it to neurological disorders such as schizophrenia and ADHD. In non-neuronal tissues, GIT1 regulates angiogenesis, cancer cell invasion, and cardiovascular functions. Its dysregulation is implicated in tumor metastasis, hypertension, and neurodevelopmental disorders.
The GIT1 antibody is widely used in techniques like Western blotting, immunofluorescence, and immunoprecipitation to study GIT1 expression, localization, and protein interactions. Researchers employ it to explore GIT1's role in signaling pathways (e.g., MAPK/ERK) and its crosstalk with cytoskeletal dynamics. Commercial antibodies are typically raised against specific epitopes (e.g., human GIT1 N-terminal or C-terminal regions) and validated for species reactivity (human, mouse, rat). Its applications span neuroscience, oncology, and cardiovascular research, aiding mechanistic studies of GIT1-associated diseases.